Luis Diaz, MD; Elizabeth Platz, ScD, MPH; and Beverly Teicher, PhD, are profiled.
On April 1, Luis A. Diaz, MD, became co–editor-in-chief of Cancer Discovery, joining Lewis Cantley, PhD. Diaz is the head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center in New York, NY. He was previously an associate professor of oncology at the Johns Hopkins University School of Medicine in Baltimore, MD. Diaz specializes in immuno-oncology and cancer genetics. His work has centered on identifying genetic predictors of response to immune checkpoint blockade, and clinical development of tests for circulating tumor DNA.
Elizabeth A. Platz, ScD, MPH, was appointed editor-in-chief of Cancer Epidemiology, Biomarkers & Prevention, effective January 1. Platz is a professor and deputy chair of the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and co-leader of the Cancer Prevention and Control Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, both in Baltimore. Platz studies mechanisms underlying the incidence and progression of prostate cancer.
Beverly Teicher, PhD, became editor-in-chief of Molecular Cancer Therapeutics on January 1. Currently the chief of the Molecular Pharmacology Branch at the NCI, Teicher previously served as vice president of oncology research at Genzyme. She was also an assistant professor of pathology at Dana-Farber Cancer Institute and an associate professor of medicine and radiation therapy at Harvard Medical School, both in Boston, MA. Her research focuses on tumor hypoxia and oxygenation, antiangiogenic agents, and drug combinations for solid tumors.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.